Filanesib combination therapy in multiple myeloma

Filanesib combination therapy in multiple myeloma Overview of the Study Filanesib is a kinesin spindle protein inhibitor that’s recently proposed as a cancer treatment for multiple myeloma. In this study of the first dose-escalation phase, the researchers tried to understand the maximum tolerated dose of two schedules of filanesib, bortezomib, and dexamethasone

pediatric leukemia patients utilizing levofloxacin

pediatric leukemia patients utilizing levofloxacin STUDY BACKGROUND Bacterial infection-related morbidity and mortality are high in children treated for acute myeloid leukemia (AML) and relapsed acute lymphoblastic leukemia (rALL). Bacteremia not only contributes to mortality but also prolongs hospitalization, delays chemotherapy, decreases the quality of life, and requires the administration of costly and

Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC

Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC Objectives To assess the effectiveness and safety of pembrolizumab monotherapy and in combination with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC).  Introduction Historically, patients with advanced NSCLC have a poor prognosis despite the use of platinum-based chemotherapy drugs. The 5-year relative survival rate of

Advanced Gastric Cancer: Prognosis With Nivolumab Monotherapy

Advanced Gastric Cancer: Prognosis With Nivolumab Monotherapy Overview  Later-line treatments for advanced gastric cancer have always been debated. Although chemotherapy is the recommended option. For the last decade, immune checkpoint inhibitors have been used for the treatment of various malignancies. Trials have also been performed for gastric cancer. In this study, a

Platinum-Resistant Recurrent Ovarian Cancer Treatment +/- Bevacizumab

Platinum-Resistant Recurrent Ovarian Cancer Treatment +/- Bevacizumab Overview Of The Study  The study aims to elucidate the efficacy of bevacizumab therapy in patients with platinum-resistant ovarian cancer whose disease has already progressed after bevacizumab plus chemotherapy therapy.  The study is a multicenter, open-label, phase II trial (JGOG3023).  Subjects were randomized 1:1 to single-agent

Metastatic Melanoma and Follow-Up MRI Scans

Metastatic Melanoma and Follow-Up MRI Scans Metastatic melanoma is an aggressive tumor, which may spread to organs either by local invasion, or lymphatic or hematogenous dissemination. Central Nervous System (CNS), especially the brain, account for up to 50% of metastasis. Skin, lymph nodes, lung, and liver are other commonly involved organs,

Isatuximab Treatment in Refractory T-Acute Lymphoblastic Leukemia

Isatuximab Treatment in Refractory T-Acute Lymphoblastic Leukemia The difficulty of making an accurate prognosis of acute T- cell lymphoblastic leukemia (T- ALL) and T- cell lymphoblastic lymphoma (T- LBL) in seniors and patients with relapsed illness has always been an issue in the medical field. Since there is no specified standard

Filanesib combination therapy in multiple myeloma